• Canopy Growth would license and exclusively sell certain Skinvisible Pharmaceutical topical products in Canada while having first rights to market those products in all countries except China and the U.S.
• Skinvisible to develop Invisicare® technology hemp-based products to be sold under license by Canopy Hemp Corporation in Canada
• Skinvisible’s Invisicare® technology cannabis-based topical products in the future, if and when THC- and CBD-infused products are legalized in Canada, are also in the agreement

Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) and Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF) have announced a definitive agreement for Canopy to license and have exclusive marketing rights to Skinvisible’s topical treatments in Canada (http://dtn.fm/N25lZ). Canopy shall have the first right of refusal to do the same for all other countries, except for China and the United States.

The agreement concerns Skinvisible’s two distinct product lines made of Invisicare® technology. Skinvisible will create unique topical hemp-based products to be launched by Canopy Hemp Corporation in Canada. Further, it would call for potential cannabis-based topical products, using Invisicare® technology when and if regulations allow the sale of CBD- or THC-infused topical products in Canada.

Skinvisible Pharmaceuticals is a R&D company that licenses its proprietary formulations made with Invisicare® in topically-applied products. Those products are designed to hold active ingredients on the skin for extended time periods, allowing for controlled release of actives. Invisicare® is a technology with 14 international patents and is able to offer improved delivery of ingredients (CBD or THC). The company notes that demand for topically-delivered cannabis is growing.

Canopy Growth is a diversified cannabis company that offers curated cannabis in dried, oil, and capsule forms. The company, which has numerous greenhouses and other production facilities, has already entered numerous partnerships with leading firms for sales in Canada and abroad. Canopy Growth has interests and operations on four continents globally and sells cannabis products, conducts R&D and educates healthcare practitioners.

“This agreement will have an immediate impact on our hemp product lines as this proven technology can be applied to a hemp oil product in today’s regulatory environment,” said Mark Zekulin, president of Canopy Growth.

President Terry Howlett of Skinvisible added, “This agreement with Canopy Growth Corporation is a significant milestone for Skinvisible. Canopy Growth is the leader and innovator in the cannabis space with over half a million feet of GMP-certified cannabis cultivation, a robust hemp operation, multiple commercialized brands in Canada, and rapid international expansion and partnerships underway including Germany, Australia, Brazil, Chile, Denmark and Spain.”

For more information, visit the company’s website at www.CanopyGrowth.com

• CIIX is pursuing the $7.2 billion legal cannabis market with hemp-based cannabidiol (CBD) products; CIIX showed a 76% year-over-year operating revenues gain in FY2017
• Dickman previously served as CFO from 2010-2016; Warren Wang, CIIX’s CEO, said Dickman will “build an infrastructure that supports long-term growth”
• CIIX has plans to launch a hemp-based line of skin care products in China by year-end 2017 and is already marketing a line of hemp-infused cannabidiol products, “OptHemp,” through its U.S. subsidiary

ChineseInvestors.com, Inc. (OTCQB: CIIX) announced in an 8K SEC filing (http://dtn.fm/Sd9Dy) that Paul Dickman has returned as its chief financial officer, effective September 25, 2017. He served earlier as CFO of the company from July 2010 through October 2016. In his new position, he remains on the company’s board of directors and, as CFO, will now also be responsible for leading CIIX’s financial operations as well as instituting the company’s financial plan and strategies.

CIIX is aggressively pursuing the $7.2 billion legal cannabis market (http://dtn.fm/KTq4i) with hemp-based cannabidiol (CBD) products targeted at the global Chinese-speaking community. By the end of 2017, it plans to market a hemp-infused skin care line in China through its CBD Biotechnology Co., Ltd. subsidiary. It is already marketing its OptHemp line of hemp oil-based products through its U.S. subsidiary, ChineseHempOil.com, Inc.

CIIX’s goal is to become the primary Chinese publicly traded company offering real-time financial information on its website. It conducts research & development on cannabidiol, as well as providing global retail distribution to the Chinese-speaking community. It has an online store based in the free trade zone of Shanghai, China, and plans to open a brick-and-mortar unit in San Gabriel, California. It markets hemp-based, legalized cannabidiol and other health products as well as planning the debut of a subscription website which will have the latest news on cryptocurrencies, such as bitcoin.

CIIX’s year-over-year operating revenues grew by 76% in FY2017. The consumer market for hemp-derived cannabidiol products is projected to grow at a 55% compound annual growth rate (CAGR) from $170 million in 2016 to $1 billion within three years (http://dtn.fm/fIoH8). Consilium Global Research projects that CIIX sales will reach $14.8 million by FY2020, skyrocketing at a CAGR of nearly 100% (http://dtn.fm/d6wNC). It also projects that the global CBD industry will reach $2.1 billion in consumer sales by 2020, propelled by a CAGR of about 80%.

“We are incredibly fortunate that Paul has agreed to return as our Chief Financial Officer,” Warren Wang, founder and CEO of CIIX, stated in a news release. “We look forward to his contributions in the financial and contractual management of the Company’s growth. Moreover, Paul shares our passion for excellence, innovation and entrepreneurial thinking. I am confident that Paul will serve effectively as our CFO just as he did in the past, helping us to build an infrastructure that supports long-term growth.”

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Innovative Global Reserve Platform enables seamless international payments
• “Banking in a box” Global Reserve Platform provides full front-to-back office processing for banks
• Solutions serve the global logistics industry, high-risk sectors and more

In a recent interview (http://dtn.fm/S87yv) with NetworkNewsWire, Global Payout, Inc. (OTC: GOHE) CEO James Hancock detailed where the innovative payment solutions company has been, where it is now, and where it plans to be in the future.

Global Payout is a frontrunner in the FINTECH revolution (http://dtn.fm/B8cnL), offering versatile and innovative solutions for domestic and international organizations distributing money on a global scale. The company’s solutions include a cutting-edge “banking in a box” fintech payment system designed for online and mobile applications. This Global Reserve Platform solution enables account holders to maximize a full array of financial services while reducing operational costs.

This FINTECH system was built on the foundation of Global Payout’s original online payment platform, the Consolidated Payment Gateway (CPG). Introduced in 2014, the CPG made it possible for enterprise clients to transfer money to international bank accounts, mobile accounts and prepaid card accounts.

Global Payout’s origins date back to 2009, when it was founded as a prepaid card company, as Hancock explains in the interview. As Global Payout began dealing with international companies, it was realized that international connections were needed to properly serve them. Global Payout was obliged to go outside of the United States to acquire international issuing banks, as well as Visa and MasterCard.

Company leaders realized that while prepaid cards were good, what the world needed was a platform that enabled the movement of money to bank accounts in particular countries. Businesses were in need of an immediate and more responsive means of paying certain employees than was afforded by prepaid cards.

Rising to the occasion, Global Payout began developing the CPG to meet business-to-business needs rather than business-to-consumer. The platform enabled businesses to quickly, efficiently and cost-effectively make payments to employees and other individuals who lived outside the United States. Subsequent enhancements to the CPG have resulted in Global Payout’s Global Reserve Platform, which has integrated bank networks worldwide and, thereby, simplified the process of transferring money between businesses on an international scale.

This web-based platform:

• Has provisions for blockchain technology within virtual currency markets, including bitcoin
• Adopts 26 foreign languages at present
• Performs currency exchange on a global level
• Offers KYC compliance for all account holders and merchants

As Global Payout continues to grow, its efforts to identify the most profitable business segments have also increased. Current primary targets for the company include:

• Logistics and shipping
• International travel companies
• Banks
• Small to medium-sized businesses
• The cryptocurrency and marijuana industries

A lack of fast and cost-effective payment options for companies in these industries opens the way for Global Payout to experience great success. The response from logistics leaders, for instance, has been exceptional. The efficacy of the Global Reserve Platform as a solution for supply chain companies is illustrated by a licensing agreement Global Payout recently signed with Cagney Global Logistics. Global Payout is also in negotiations with commercial banks, cannabis enterprises and entities in the cryptocurrency market.

For more information, visit the company’s website at www.GlobalPayout.com

Let us hear your thoughts: Global Payout, Inc. Message Board

• Versatile extraction process applicable to both water-wet and oil-wet sands
• Green technology will save wildlife
• Closed loop technology uses less water than traditional open loop processes

Tailings ponds, despite an innocuous name that makes them sound like an amusement park feature, are anything but amusing. They are as potentially treacherous as serpents hidden in the grass and remain so only because news reporting on their alarming threat has been scant. Containing mammoth quantities of residual toxic sludge, tailings ponds scar the landscapes already disturbed by the oil-sands industry. As if to highlight their destruction, many in Alberta, the hub of Canada’s industry, are decorated with bizarre orange anthropomorphic figures. These scarecrows are a feeble attempt to keep birds away. Many do not and perish slowly, ensnared by the paralyzing paste. Nevertheless, the peril to the environment posed by tailings ponds may soon abate. Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) has developed a unique, environmentally-safe, continuous flow, closed loop technology – a first in North America and probably in the world – that is likely to make tailings ponds for oil sands a relic of the past.

A tailings pond is a wet storage area for the unwanted residual material or ‘tailings’ left behind after mining and extracting resources, such as bitumen from oil sands. Tailings ponds allow the tailings to be continuously submerged, although some tailings can be ‘dry covered’ under soil. They are usually engineered structures but, in some instances, natural bodies of water have been turned into such dumps, which altogether ‘now cover 176 square kilometres and hold enough liquid to fill the equivalent of 390,000 Olympic-sized swimming pools’, according to the Toronto Star (http://dtn.fm/BCll2). CBC News has reported on a Canadian government federal study of 2014 that found ‘Alberta’s oil sands are polluting ground water and seeping into the Athabasca River’ (http://dtn.fm/z3eZ2). The extraction process developed by Petroteq could put an end to all that, since the technology is closed loop.

Petroteq Energy is focused on the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits, and, so, its oil-sands extraction technology does not require tailings ponds. The only elements that ever leave the closed-loop system are the extracted crude oil and the cleaned sands, which can be placed back in the earth or sold as clean sand for construction or fracking purposes.

This extraction technology is the result of almost five years of research by Petroteq’s research and engineering teams, headed up by the company’s chief technology officer, Dr. Vladimir Podlipskiy, well known for his work with benign solvents. During this time, Petroteq has gradually enhanced and improved the efficiencies of its technology at each stage of fabrication with better dryer/mixer components and a higher consistency of oil sands flow. The extraction technology is versatile; it can be effectively applied to both “water-wet” deposits, such as the oil sands in Alberta, Canada, or “oil-wet” deposits, such as the resources typically found in Utah.

It also solves the water problem. Processing oil sands requires large volumes of water, ‘about 3 barrels of fresh water to produce one barrel of oil’, according to Oil Sands Magazine (http://dtn.fm/qH4II). This poses a particular challenge to western U.S. states like Utah, which are relatively arid. Petroteq’s extraction technology utilizes no water in the extraction process. It also produces no greenhouse gases and requires no high temperatures or pressures. In addition, the technology extracts up to 99 percent of all hydrocarbon content and recycles almost all the benign solvents. This certainly looks like technology that could protect the environment and the droves of geese, ducks, swans, and other species that cannot tell the difference between a tailings pond and a sparkling spring.

For more information, please visit www.Petroteq.energy

• Name change to EVIO, Inc., from Signal Bay, Inc., reflects fact that EVIO Labs division generates majority of company volume
• New ticker symbol of EVIO will become effective October 3, 2017, for the legalized cannabis industry’s quality control testing and ancillary advisory services company
• Reverse stock split is positioned to attract institutional investors to provide funding for company’s vision of becoming a leading biotechnology firm in the cannabis industry

EVIO, Inc. (OTCQB: SGBYD) has changed its name from Signal Bay, Inc. and also announced a reverse stock split (http://dtn.fm/Set9Z). The life science company will also have a new ticker symbol, EVIO, effective October 3, 2017, pending approval. EVIO Labs provide the cannabis industry with accredited analytical testing and scientific research.

EVIO engineered the 1:100 reverse stock split in order to reduce its outstanding shares from three billion to one billion. After the split, the par value of each share of common stock remains unchanged.

“We are excited about the future direction of the Company, under the new name of EVIO, Inc.,” William Waldrop, EVIO CEO, stated in a news release. “We aligned the corporate name with our EVIO Labs Division which accounts for a majority of our revenue and lays a foundation for becoming a leading cannabis biotechnology company. Furthermore, with the effectiveness of the reverse stock split, we structured the company to be best positioned for institutional investors to provide the necessary funding to complete our vision. These are exciting times to be part of the fastest growing industry in the world, and EVIO is now positioned to take full advantage of this opportunity.”

Additionally, the company has licensed its brand and cannabis technology in Colorado to Phytatech CO, LLC. Phytatech will now operate under the EVIO Labs brand (http://dtn.fm/BSrz4).

For more information, visit the company’s website at www.EVIOLabs.com

• Provisional patent application protects unique process yielding pharmaceutical grade, bio-identical cannabinoids
• Proprietary research allows production of synthetic cannabinoids for therapeutic use with certain diseases
• Early stage clinical trials are expected to begin in 2018 for a drug targeting a rare children’s skin disorder

Imagine having a painful disease that causes your skin to blister at the slightest minor injury. Even just scratching an itch or accidentally rubbing against a rough object could cause peeling blisters and acute suffering. Epidermolysis bullosa, a genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States, currently has no approved treatments, according to the Dystrophic Epidermolysis Bullosa Research Association of America. Researchers at InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), however, hope to treat this unmet medical need with a topical drug called INM-750 that includes multiple biosynthesized cannabinoids as its active ingredients.

Vancouver, Canada-based InMed Pharmaceuticals is a preclinical biotech company that specializes in developing novel drug therapies by manufacturing cannabinoids with the potential to have a therapeutic effect on specific diseases. The company’s biosynthesis platform works by inserting the plant’s DNA into E. coli bacteria that has the internal ability to manufacture specific cannabinoid compounds.

Couple this approach with a proprietary bioinformatics data assessment tool created by InMed Pharmaceuticals, and the possibilities are endless. In its corporate presentation, the company details the potential benefits of biosynthesis of cannabinoids as wide-ranging, noting that the procedure could enable enhanced quality control and purification while unlocking the minor cannabinoids that are currently too difficult and expensive to produce and study (http://dtn.fm/p2h5Y).

Glaucoma, one of the world’s leading causes of blindness, is another life-changing disease that InMed’s proprietary research is zeroing in on. InMed’s INM-085 biosynthesized, topical glaucoma treatment will be the first of its kind – utilizing numerous cannabinoids for optimal efficacy as it treats the affected eye’s cells and optic nerve tissues. The company projects the potential revenue for these two drugs alone at $6 billion a year (http://dtn.fm/MvG2I).

But there are other, equally devastating diseases that InMed Pharmaceutical researchers propose targeting in their quest to biosynthesize therapeutic drugs from cannabis and other botanical sources. Rheumatoid arthritis, epilepsy, asthma and diabetes are some of the more well-known names. The benefits of using InMed’s proprietary biosynthesis procedure to manufacture any of the 90-plus identified cannabinoids in marijuana reads like a wish list for investors:

• There are significant cost savings versus the traditional method of growing thousands of plants and then extracting cannabinoids
• Quality control, which includes enhanced production and purification, means a superior, standardized product
• InMed’s comprehensive database uses a bioinformatics platform to select specific cannabinoid combinations that may help treat targeted diseases
• Preclinical formulation of therapy drugs this year will lead to expected clinical trials in 2018

Leading research estimates set the 2016 legal cannabis market in North America anywhere from $6.7 billion to $7.2 billion. Growth projections are also “off the charts,” as a stunning compound annual sales growth rate of 25 percent is expected through 2021, and a $50 billion global market is considered possible by 2025 (http://dtn.fm/2kPMv).

Looking ahead, InMed Pharmaceuticals President and CEO Eric A. Adams said he believes the company’s technology will have a huge impact on the booming cannabis industry.

“When I saw the technology that InMed has, I knew right away that it was going to be something big,” Adams said in a recent interview published in MERRY JANE, an online resource for news, culture and video covering cannabis. “The science behind the company is a real game changer (http://dtn.fm/Yt7UT).”

In a move to strengthen the company’s core, InMed has also retained the consulting services of Ben Paterson, P.E., who will assist in defining the pathway for the scale-up, purification and manufacturing strategies for the company’s cannabinoid biosynthesis program. Patterson is a principal consultant at PatersonChemE Consulting, LLC.

Paterson has nearly four decades of experience in developing pharmaceutical manufacturing and purification processes. He previously spent 37 years with Eli Lilly and Company as a senior engineering advisor, including 24 years in the biosynthesis division. His expertise includes first defining processes in the lab, then scaling up to pilot and commercial scale.

“Mr. Paterson brings significant experience in all facets of biosynthesis manufacturing and facility design,” Adams said in a news release announcing Paterson’s appointment (http://dtn.fm/18EUn). “His expertise directing complex capital projects, overseeing facilities and equipment, and interfacing with various stakeholders will be a significant asset to InMed.”

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

• At least 150 million Americans play games
• Business accelerator for mobile app developers
• Footprint in the mammoth video games market

With the latest Entertainment Software Association (ESA) report revealing that half of America plays video games, the excitement surrounding AppSwarm, Inc.’s (OTC: SWRM) foray into the industry appears to be based on very robust rationales. AppSwarm is a business accelerator focused on acquiring software applications for all forms of devices. The company actively pursues partnerships with software development companies that exhibit historical profitability and growth capability. Leveraging its resources in capital, management, marketing and product development, AppSwarm is able to add value to the collaboration. Now with a portfolio of entertainment software apps, AppSwarm is showing it’s ahead of the game in what continues to be a highly lucrative industry.

When psychiatrist Eric Berne wrote in 1964 about the “Games People Play,” giving an account of his study into the psychology of human relationships, it was apparent that he must have glimpsed into the extent to which games provide comfort and a sense of identity. Largely addressed to adults, Berne’s work was a reminder of how naturally we take to games; nothing is as easy as child’s play. These inclinations do not fall away quickly. The average age of the video game player is not some teenage number, but 35, and more women 18 years and over play video games than boys under the age of 18, according to the ESA 2017 report (http://dtn.fm/57oPL).

Again, contrary to public perception, only about one-quarter of gamers are under 18; most gamers are adults. In all, ‘more than 150 million Americans play video games, and 65 percent of American households are home to at least one person who plays video games regularly, or at least three hours per week,’ As will be expected, the economic consequences of the games people play are considerable. ‘In 2016, the industry sold over 24.5 billion games and generated more than $30.4 billion in revenue. Total game sales included purchases of digital content such as online subscriptions, downloadable content, mobile applications, and social networking games.’ Overall, ‘computer and video game companies provided jobs to more than 220,000 people in 50 states.’

With such a huge demand for games, developers are hard pressed to get their creations to market and often rely on accelerators like AppSwarm. Sometimes confused with business incubators, business accelerators are an entirely different animal. While incubators focus on getting ideas off the ground, an accelerator helps a business that’s already running run better. As this piece in Inc. explains (http://dtn.fm/Mc9tb), ‘while incubators help companies stand and walk, accelerators teach companies to run.’ AppSwarm targets businesses that have not only a promising future, but also a good past.

AppSwarm employs a proprietary screening process, called the Swarm, to select the companies with which it would like to work. These collaborations can take one of several forms: stock purchase agreements, royalty agreements, joint ventures, partnerships or acquisitions. The company offers complete, end-to-end services for mobile application development across all major platforms, including Apple iPhone, RIM’s BlackBerry, Google’s Android, and Microsoft’s Windows Mobile, and it has agreements in place with all of the major application stores. AppSwarm will act as a partner to increase marketing visibility, in addition to providing the range of resources that small firms, young entrepreneurs and application developers need to commercialize their applications effectively.

So far, AppSwarm has been winning its game. It’s current game portfolio includes Turtles, Huh?, which was ranked as the top iOS family games app in five countries, ranked in the top five iOS family games apps in 22 countries and ranked in the top 10 iOS family games apps in 44 countries.

For more information, visit the company’s website www.App-Swarm.com

Let us hear your thoughts: AppSwarm, Inc. Message Board

• Clinical-grade full spectrum hemp oil products created for licensed medical practitioners included
• Science-backed education, superior products meet requirements of medical profession
• Medical cannabinoid product revenue projected to reach $1.15 billion by 2020

Grey Cloak Tech Inc. (OTC: GRCK) recently announced that it has signed a binding Letter of Intent to purchase Eqova Life Sciences, a Colorado-based medically-focused company producing clinical-grade full spectrum hemp oil products. To date, no other hemp oil company has exclusively focused on the medical practitioner market, leaving this important segment largely underserved. Grey Cloak Tech, which is known for its click fraud prevention products, has been searching for a way to enter the growing cannabinoid industry, as it noted in a news release (http://dtn.fm/E4cx1).

According to The Hemp Business Journal, sales of products derived from cannabinoids more than tripled from 2014 to 2017, rising to $358 million. Additional revenue predictions for the medical marijuana industry point to $1.8 billion in sales by 2022, the report states. Grey Cloak Tech expects to dominate the medical practitioner market with science-backed education and superior products that utilize standardized dosing and unique delivery methods. Market professionals rightly require a safe, consistent product that meet strict conditions.

Eqova CEO Patrick Stiles, who is responsible for founding and growing several nutraceutical brands, has sold millions of dollars in products online through a variety of channels. Eqova’s medical advisory board seeks the most effective phytocannabinoid-rich hemp oil, ingredients and delivery methods – combining them into innovative, cutting edge products that deliver standardized dosing and consistent pharmaceutical grade ingredients that actually help patients. All Eqova products go through rigorous third-party testing before and after manufacturing, ensuring that Equova’s products contain no or only trace amounts of psychoactive ingredients such as THC (tetrahydrocannabinol).

“Today, consumers are smarter than ever before. They demand superior products but also want it backed up with education,” Stiles said in a news release. “The days of empty promises are over. This is why we exclusively partner with medical professionals to bring our full spectrum hemp oil products to their patients.”

William Bossung, CFO of Grey Cloak Tech, said the acquisition is contingent on meeting various obligations and conditions and will be consummated as soon as is reasonably practicable.

“The possibility of growing substantial revenues certainly exists with Equova,” Bossung said. “With Mr. Stiles’ business savvy, we expect to have substantial increases in revenue.”

For more information on Grey Cloak Tech Inc., visit www.GreyCloakTech.com

For information about Eqova Life Sciences, visit www.Eqova.com

• LTTGF board member Kevin Harrington, original star of hit series ‘Shark Tank’ and infomercial pioneer, talked to Benzinga about growing LTTGF into 20+ additional states, using celebrity endorsements and implementing a “360 degree” strategy to raise profile and attract new customers
• U.S. lottery industry is estimated to be between $70 billion and $80 billion nationally, with California, initial state for LTTGF operations, a $6.3 billion lottery market
• LTTGF has named celebrity William Shatner, actor and Star Trek star, as its spokesperson; Shatner represented The Priceline Group (NASDAQ: PCLN) for 14 years, helping to build its stock from an IPO of $16 per share to $1,862 today with a market cap of $91.3 billion

LottoGopher Holdings Inc. (OTCQB: LTTGF) (CSE: LOTO) (FRA: 2LG) board member Kevin Harrington, former ‘Shark Tank’ star and a pioneer of the infomercial industry, told investors on Benzinga (http://dtn.fm/b4JZC) that they should keep an eye open to attractive entry points to the stock. “I’m an optimistic investor and I like to get involved at the right time,” he said.

LTTGF currently operates in the $6.3 billion California market (http://dtn.fm/L4jhH) as a lottery messenger service that permits users to buy state lottery tickets online via credit and debit cards, manage their accounts and receive the latest lottery news. The company has identified 22 more states which it plans to enter. Eventually, it hopes to expand into the national U.S. lottery market (http://dtn.fm/8lQRi).

“We are operating a service to help people get tickets,” Harrington told Benzinga. “I call it the ‘Uber Eats’ of lotteries. We do a similar thing: You want a lottery ticket, you go online and order it, we go and handle it getting printed for you and put it in your account…It’s like an on-demand courier service.”

He added that the company’s focus is raising its profile and acquiring more customers. “Our vision is to become the leading lottery messenger service in the United States,” said James Morel, founder and CEO of the company.

“We’ll be taking a 360 degrees approach to getting customers at a number that is less than the lifetime value of a customer, so that we can get a profit in the process,” Harrington said. “LottoGopher will be using TV, radio, digital media, celebrity endorsements…all the resources that are available…Each particular medium will focus on a particular demographic.”

LTTGF is offering players in California state lotteries such as MEGA Millions, SuperLotto Plus and POWERBALL. Participants can avoid waiting and buy tickets online after registering and paying a subscription fee. There are no other commissions or hidden fees. Bitcoin and ethereum are also accepted.

Harrington said that LTTGF will be seeking to enter more states and acquire additional customers. “This plays right into my background, which is finding customers. This is what we are working on right now. We have dozens of things happening as we speak, and over the next 60 days, that are pretty groundbreaking.”

LTTGF also recently named William Shatner as its spokesperson (http://dtn.fm/2cJtz). Shatner is best known for his role in Star Trek, but he has also appeared in Boston Legal and T.J. Hooker, as well as numerous stage productions and movies. Shatner, in 1997, was named spokesperson for Priceline (NASDAQ: PCLN). That stock skyrocketed from an IPO price of $16 per share to its current PPS of $1,862. Today, the company has a market cap of $91.3 billion.

For more information, visit the company’s website at www.LottoGopher.com

Let us hear your thoughts: LottoGopher Holdings Inc. Message Board

• Aaron Keay, CEO, says plans set for greater production capacity and strategy for global distribution in emerging markets
• Expansion of ABcann’s Vanluven facility underway, along with construction of the company’s 150,000 sq. ft. Kimmett facility
• Napanee, Ontario-based firm uses proprietary plant-growing technology and is pursuing opportunities in Australia and Germany

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) achieved working capital of $43 million from multiple financings, including private placements and strategic partnerships, during the six months ended June 30, 2017, it announced on August 29 (http://dtn.fm/RHe5K).

ABcann manufactures and distributes medical cannabis under a license issued by Health Canada to a wholly-owned subsidiary of the company, ABcann Medicinals, Inc. It is currently expanding and constructing facilities to grow more product, in addition to exploring other opportunities of multiple delivery vehicles.

The company specializes in growing cannabis within environmentally controlled chambers which can monitor and control all variables. The result is organically grown and pesticide-free plants that are featured in products boasting consistent quality standards.

“ABcann’s first quarter as a publicly traded issuer was a successful one, leading to the company having over $40 million in current working capital,” CEO Aaron Keay noted in a news release. “With our strong cash position, ABcann expects to significantly increase production capacity in 2018 while pursuing our aggressive construction and expansion timelines at both Vanluven and Kimmett.”

For the three months ended June 30, 2017, ABcann recorded revenues of C$264,319, as compared to $21,465 for the same period last year. For the six months ended June 30, 2017, revenues were $436,802, as compared to $21,840 for the comparable period in 2016.

For more information, visit the company’s website at www.ABcann.ca

Let us hear your thoughts: ABcann Global Corp. Message Board